Ignite Creation Date:
2025-12-25 @ 5:06 AM
Ignite Modification Date:
2025-12-26 @ 4:10 AM
Study NCT ID:
NCT01605227
Status:
COMPLETED
Last Update Posted:
2018-03-14
First Post:
2012-05-22
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Sponsor:
Exelixis
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
XL184-307
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None